Overview

Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)

Status:
Completed
Trial end date:
2017-06-04
Target enrollment:
Participant gender:
Summary
The trial is an open-label, 4 cohorts, sequential, dose-escalating, single dose trial.
Phase:
Phase 1
Details
Lead Sponsor:
Pharmacosmos A/S
Treatments:
Iron
Iron isomaltoside 1000